Liberty BioSecurity Senior Advisory Board Member, Dr. Ari Patrinos, is the Director of the Center for Urban Science and Progress, and a professor of biological, chemical and mechanical engineering at NYU. He is considered to be a leading authority on structural biology, genomics, global environmental change, and nuclear medicine. This oral history follows his time as Director of the Office of Biological and Environmental Research in the U.S. Department of Energy (DOE), where he worked on the Human Genome Project and initialed the International Panel on Climate Change and the Global Change Research Program. In this interview Ari discusses how the DOE ended up working with NIH on the Human Genome Project, his research, and his relationships with Francis Collins, Craig Venter and Harold Varmus.
Liberty’s Expeditionary Science and Special Programs Laboratory (X-Lab) develops bioengineering and clinical solutions to challenging medical, commercial and industrial unmet needs. These solutions are derived from novel organisms obtained from government and Liberty's own proprietary collection of extremophile biologics. The X-Lab's multidisciplinary team of microbiologists and bioinformaticians are supported by physicians and experts drawn from military and intelligence communities.
Liberty Biosecurity has developed a proprietary biological drug compound that degrades polymicrobial biofilms produced by pathogens in human wounds. Internally designated as Advanced Decontamination and Bio-Neutralization Material (ADBM), this compound is being developed into a portfolio of compound derivatives targeted at multiple types of pathogenic biofilms.
ADBM will be submitted to the U.S. Food and Drug Administration as an Investigative New Drug, with the indication of use as a topical therapy to enhance wound healing in neuropathic diabetic foot ulcers. Globally, this condition afflicts up to 35% of the 422 million people living with diabetes, while in the US alone, diabetic limb complications result in an annual direct cost of $17 billion/year.
At Meeting Room no.2, Office of the Dean, Faculty of Medicine Ramathibodi Hospital, Prof. Piyamitr Sritara, Dean of Faculty of Medicine together with Mr. Jason Anderson, Chief Executive Officer of Liberty Biosecurity, LLC and Mr. Marek Stepniak, President of CP Medical Center Co., Ltd., signed the Memorandum of Understanding on behalf of their respective cooperates on November 14, 2018.
Organized at the Faculty Meeting Room, Administration Building, 2nd floor, Prof. Dr. Prasit Wattanapa, Dean of Faculty of Medicine together with Mr. Jason Anderson, Chief Executive Officer of Liberty Biosecurity, LLC and Mr. Marek Stepniak, President of CP Medical Center Co., Ltd., signed the Memorandum of Understanding on behalf of their respective cooperates on November 13th, 2018. The MOU contains a detailed framework for cooperation in research and the establishment of Joint Research Program on Cancer Precision Medicine.
In the 15 years since the Human Genome Project first exposed our DNA blueprint, vast amounts of genetic data have been collected from millions of people in many different parts of the world. Carlos D. Bustamante’s job is to search that genetic data for clues to everything from ancient history and human migration patterns to the reasons people with different ancestries are so varied in their response to common diseases.
Noninvasive test may screen for disease before symptoms appear
By Jim Dryden
It may be possible in the future to screen patients for Alzheimer’s disease using an eye exam.
Using technology similar to what is found in many eye doctors’ offices, researchers at Washington University School of Medicine in St. Louis have detected evidence suggesting Alzheimer’s in older patients who had no symptoms of the disease.
Their study, involving 30 patients, is published Aug. 23 in the journal JAMA Ophthalmology.
“Finding the Code,” the first in a three-part series with STAT, tells the story of one of biology’s most spectacular achievements. The race to sequence the human genome was billed as a way to end disease. Here’s where it led.
Authors: Paras Lakhani, MD, Adam B. Prater, MPH, MD, R. Kent Hutson, MD, Kathy P. Andriole, PhD, Keith J. Dreyer, DO, PhD, Jose Morey, MD, Luciano M. Prevedello, MD, MPH, Toshi J. Clark, MD, J. Raymond Geis, MD, Jason N. Itri, MD, PhD, C. Matthew Hawkins, MD Much attention has been given to machine learning and its perceived impact in radiology, particularly in light of recent success with image classification in international competitions. However, machine learning is likely to impact radiology outside of image interpretation long before a fully functional “machine radiologist” is implemented in practice. Here, we describe an overview of machine learning, its application to radiology and other domains, and many cases of use that do not involve image interpretation. We hope that better understanding of these potential applications will help radiology practices prepare for the future and realize performance improvement and efficiency gains.